Cardiac Blood-Based Biomarkers of Myocardial Stress as Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source/Cryptogenic Stroke: A Systematic Review and Meta-Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Undiagnosed atrial fibrillation (AF) is a major risk factor for stroke that can go unnoticed in individuals with embolic stroke of undetermined source (ESUS) or cryptogenic stroke (CS). Early detection is critical for stroke prognosis and secondary prevention. This study aimed to determine if blood biomarkers of myocardial stress can accurately predict AF in patients with ESUS/CS, which would allow the identification of those who would benefit from closer monitoring. Methods In February 2023 we performed a systematic date-unrestricted search of three databases for studies on patients with ESUS/CS who were subsequently diagnosed with AF. We examined the relationships between AF and serum myocardial stress markers such as brain natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), midregional proatrial natriuretic peptide, and troponin. Results Among the 1,527 studies reviewed, 23 eligible studies involving 6,212 participants, including 864 with AF, were analyzed. A meta-analysis of 9 studies indicated that they demonstrated a clear association between higher NT-proBNP levels and an increased risk of AF, with adjusted and raw data indicating 3.06- and 9.03-fold higher AF risks, respectively. Lower NT-proBNP levels had a pooled negative predictive value of 91.7%, indicating the potential to rule out AF with an 8% false-negative rate. Conclusions Further research is required to fully determine the potential of biomarkers for AF detection after stroke, as results from previous studies lack homogeneity. However, lower NTproBNP levels have potential in ruling out AF in patients with ESUS/CS. Combining them with other relevant biomarkers may enhance the precision of identifying patients who will not benefit from extended monitoring, which would optimize resource allocation and patient care.
Abstract
Background and Purpose Undiagnosed atrial fibrillation (AF) is a major risk factor for stroke that can go unnoticed in individuals with embolic stroke of undetermined source (ESUS) or cryptogenic stroke (CS). Early detection is critical for stroke prognosis and secondary prevention. This study aimed to determine if blood biomarkers of myocardial stress can accurately predict AF in patients with ESUS/CS, which would allow the identification of those who would benefit from closer monitoring. Methods In February 2023 we performed a systematic date-unrestricted search of three databases for studies on patients with ESUS/CS who were subsequently diagnosed with AF. We examined the relationships between AF and serum myocardial stress markers such as brain natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), midregional proatrial natriuretic peptide, and troponin. Results Among the 1,527 studies reviewed, 23 eligible studies involving 6,212 participants, including 864 with AF, were analyzed. A meta-analysis of 9 studies indicated that they demonstrated a clear association between higher NT-proBNP levels and an increased risk of AF, with adjusted and raw data indicating 3.06- and 9.03-fold higher AF risks, respectively. Lower NT-proBNP levels had a pooled negative predictive value of 91.7%, indicating the potential to rule out AF with an 8% false-negative rate. Conclusions Further research is required to fully determine the potential of biomarkers for AF detection after stroke, as results from previous studies lack homogeneity. However, lower NTproBNP levels have potential in ruling out AF in patients with ESUS/CS. Combining them with other relevant biomarkers may enhance the precision of identifying patients who will not benefit from extended monitoring, which would optimize resource allocation and patient care.
참고문헌 (48)
- Hart RG, "Embolic strokes of undetermined source : the case for a new clinical construct", Lancet Neurol, 13, pp.429~438 (2014)
- Saver JL, "Cryptogenic stroke", N Engl J Med, 374, pp.2065~2074 (2016)
- Sanna T, "Cryptogenic stroke and underlying atrial fibrillation", N Engl J Med, 370, pp.2478~2486 (2014)
- Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)
- Yaghi S, "Atrial cardiopathy : a mechanism of cryptogenic stroke", Expert Rev Cardiovasc Ther, 15, pp.591~599 (2017)
- Kamel H, "Atrial cardiopathy : a broadened concept of left atrial thromboembolism beyond atrial fibrillation", Future Cardiol, 11, pp.323~331 (2015)
- Diamantopoulos A, "Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke", Int J Stroke, 11, pp.302~312 (2016)
- Oikonomou E, "Biomarkers in atrial fibrillation and heart failure", Curr Med Chem, 26, pp.873~887 (2019)
- De Marchis GM, "Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke", Neurology, 90, pp.e455~e465 (2018)
- Yaghi S, "Early elevated troponin levels after ischemic stroke suggests a cardioembolic source", Stroke, 49, pp.121~126 (2018)
- Dilaveris PE, "Silent atrial fibrillation : epidemiology, diagnosis, and clinical impact", Clin Cardiol, 40, pp.413~418 (2017)
- Llombart V, "B-type natriuretic peptides help in cardioembolic stroke diagnosis : pooled data meta-analysis", Stroke, 46, pp.1187~1195 (2015)
- Yang HL, "Predicting cardioembolic stroke with the B-type natriuretic peptide test : a systematic review and meta-analysis", J Stroke Cerebrovasc Dis, 23, pp.1882~1889 (2014)
- Wasser K, "Brain natriuretic peptide and discovery of atrial fibrillation after stroke : a subanalysis of the Find-AFRANDOMISED trial", Stroke, 51, pp.395~401 (2020)
- Kamtchum-Tatuene J, "Blood biomarkers for stroke diagnosis and management", Neuromolecular Med, 21, pp.344~368 (2019)
- Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- "Study quality assessment tools"[URL]
- "MetaXL user guide (version 5.3)"[URL]
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
- "Mada: meta-analysis of diagnostic accuracy (version 0.5.11)"[URL]
- Kitayama K, "Frequent supraventricular premature contractions are an independent predictor for detection of atrial fibrillation in patients with embolic stroke undetermined source", Hirosaki Med J, 72, pp.43~50 (2022)
- Doijiri R, "Different aspects of early and late development of atrial fibrillation during hospitalization in cryptogenic stroke", Sci Rep, 11, pp.7127~ (2021)
- Kusunose K, "Predictive value of left atrial function for latent paroxysmal atrial fibrillation as the cause of embolic stroke of undetermined source", J Cardiol, 78, pp.355~361 (2021)
- Miyazaki Y, "Atrial fibrillation after ischemic stroke detected by chest strap-style 7-day holter monitoring and the risk predictors : EDUCATE-ESUS", J Atheroscler Thromb, 28, pp.544~554 (2021)
- Ikenouchi H, "Left ventricular abnormality and covert atrial fibrillation in embolic stroke of undetermined source", J Atheroscler Thromb, 29, pp.1069~1075 (2022)
- Pagola J, "Large vessel occlusion is independently associated with atrial fibrillation detection", Eur J Neurol, 27, pp.1618~1624 (2020)
- Palà E, "B-type natriuretic peptide over N-terminal pro-brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke", Eur J Neurol, 28, pp.540~547 (2021)
- Amaya Pascasio L, "Development of a score to predict the paroxysmal atrial fibrillation in stroke patients : the screening for atrial fibrillation scale", Front Neurol, 13, pp.900582~ (2022)
- Bahit MC, "Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source : an analysis of the RE-SPECT ESUS trial", Circulation, 144, pp.1738~1746 (2021)
- Fonseca AC, "N-terminal pro-brain natriuretic peptide shows diagnostic accuracy for detecting atrial fibrillation in cryptogenic stroke patients", Int J Stroke, 9, pp.419~425 (2014)
- Kneihsl M, "Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score-a prospective observational study", Eur J Neurol, 29, pp.149~157 (2022)
- Kneihsl M, "Blood biomarkers of heart failure and hypercoagulation to identify atrial fibrillation-related stroke", Stroke, 50, pp.2223~2226 (2019)
- Palà E, "Blood-based biomarkers to search for atrial fibrillation in high-risk asymptomatic individuals and cryptogenic stroke patients", Front Cardiovasc Med, 9, pp.908053~ (2022)
- Pikija S, "Neurologist-led management of implantable loop-recorders after embolic stroke of undetermined source", Front Neurol, 12, pp.816511~ (2021)
- Rodríguez-Yáñez M, "High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke", Neurology, 81, pp.444~447 (2013)
- Šaňák D, "Atrial fibrillation in young ischemic stroke patients : an underestimated cause?", Eur Neurol, 73, pp.158~163 (2015)
- Skrebelyte-Strøm L, "Prediction of occult atrial fibrillation in patients after cryptogenic stroke and transient ischaemic attack : PROACTIA", Europace, 24, pp.1881~1888 (2022)
- Snyman S, "Atrial fibrillation detected by implantable monitor in embolic stroke of undetermined source : a new clinical entity", J Clin Med, 11, pp.5740~ (2022)
- Vera A, "A comprehensive model to predict atrial fibrillation in cryptogenic stroke : the decryptoring score", J Stroke Cerebrovasc Dis, 31, pp.106161~ (2022)
- von Falkenhausen AS, "Atrial fibrillation risk assessment after embolic stroke of undetermined source", Ann Neurol, 93, pp.479~488 (2023)
- Doijiri R, "Paroxysmal atrial fibrillation in cryptogenic stroke patients with major-vessel occlusion", Front Neurol, 11, pp.580572~ (2020)
- Schweizer J, "Measurement of midregional pro-atrial natriuretic peptide to discover atrial fibrillation in patients with ischemic stroke", J Am Coll Cardiol, 79, pp.1369~1381 (2022)
- Jaeschke R, "Users’ guides to the medical literature. III. How to use an article about a diagnostic test B. What are the results and will they help me in caring for my patients?", JAMA, 271, pp.703~707 (1994)
- Maisel A, "State of the art : using natriuretic peptide levels in clinical practice", Eur J Heart Fail, 10, pp.824~839 (2008)
- Mueller C, "Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations", Eur J Heart Fail, 21, pp.715~731 (2019)
- York MK, "B-type natriuretic peptide levels and mortality in patients with and without heart failure", J Am Coll Cardiol, 71, pp.2079~2088 (2018)
- Rubiera M, "European Stroke Organisation(ESO)guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin", Eur Stroke J, 7, pp.CVII~CXXXIX (2022)
- Cameron A, "Biomarkers for atrial fibrillation detection after stroke : systematic review and meta-analysis", Neurology, 97, pp.e1775~e1789 (2021)
